These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 24472406)

  • 1. Influence of St. John's wort on the steady-state pharmacokinetics and metabolism of bosentan.
    Markert C; Ngui P; Hellwig R; Wirsching T; Kastner IM; Riedel KD; Burhenne J; Weiss J; Mikus G; Haefeli WE
    Int J Clin Pharmacol Ther; 2014 Apr; 52(4):328-36. PubMed ID: 24472406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.
    Wang Z; Gorski JC; Hamman MA; Huang SM; Lesko LJ; Hall SD
    Clin Pharmacol Ther; 2001 Oct; 70(4):317-26. PubMed ID: 11673747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interaction between St John's wort and an oral contraceptive.
    Hall SD; Wang Z; Huang SM; Hamman MA; Vasavada N; Adigun AQ; Hilligoss JK; Miller M; Gorski JC
    Clin Pharmacol Ther; 2003 Dec; 74(6):525-35. PubMed ID: 14663455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of induction of CYP3A4 by St John's wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotype.
    Markert C; Kastner IM; Hellwig R; Kalafut P; Schweizer Y; Hoffmann MM; Burhenne J; Weiss J; Mikus G; Haefeli WE
    Basic Clin Pharmacol Toxicol; 2015 May; 116(5):423-8. PubMed ID: 25286744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity.
    Hafner V; Jäger M; Matthée AK; Ding R; Burhenne J; Haefeli WE; Mikus G
    Clin Pharmacol Ther; 2010 Feb; 87(2):191-6. PubMed ID: 19924124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided.
    Huppertz A; Werntz L; Meid AD; Foerster KI; Burhenne J; Czock D; Mikus G; Haefeli WE
    Br J Clin Pharmacol; 2018 Dec; 84(12):2903-2913. PubMed ID: 30192025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects.
    Dresser GK; Schwarz UI; Wilkinson GR; Kim RB
    Clin Pharmacol Ther; 2003 Jan; 73(1):41-50. PubMed ID: 12545142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose.
    Mueller SC; Majcher-Peszynska J; Uehleke B; Klammt S; Mundkowski RG; Miekisch W; Sievers H; Bauer S; Frank B; Kundt G; Drewelow B
    Eur J Clin Pharmacol; 2006 Jan; 62(1):29-36. PubMed ID: 16341856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide.
    Xu H; Williams KM; Liauw WS; Murray M; Day RO; McLachlan AJ
    Br J Pharmacol; 2008 Apr; 153(7):1579-86. PubMed ID: 18204476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of Saint John's Wort (hypericum perforatum) on the urinary excretion of D-glucaric acid and 6beta-hydroxycortisol in healthy volunteers.
    Bauer S; Störmer E; Kerb R; Johne A; Brockmöller J; Roots I
    Eur J Clin Pharmacol; 2002 Dec; 58(9):581-5. PubMed ID: 12483450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of St. John's wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers.
    Hebert MF; Park JM; Chen YL; Akhtar S; Larson AM
    J Clin Pharmacol; 2004 Jan; 44(1):89-94. PubMed ID: 14681346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum).
    Johne A; Brockmöller J; Bauer S; Maurer A; Langheinrich M; Roots I
    Clin Pharmacol Ther; 1999 Oct; 66(4):338-45. PubMed ID: 10546917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of St John's wort on imatinib mesylate pharmacokinetics.
    Frye RF; Fitzgerald SM; Lagattuta TF; Hruska MW; Egorin MJ
    Clin Pharmacol Ther; 2004 Oct; 76(4):323-9. PubMed ID: 15470331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers.
    Markert C; Schweizer Y; Hellwig R; Wirsching T; Riedel KD; Burhenne J; Weiss J; Mikus G; Haefeli WE
    Br J Clin Pharmacol; 2014 Jan; 77(1):141-8. PubMed ID: 23738582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract.
    Arold G; Donath F; Maurer A; Diefenbach K; Bauer S; Henneicke-von Zepelin HH; Friede M; Roots I
    Planta Med; 2005 Apr; 71(4):331-7. PubMed ID: 15856409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The recovery time-course of CYP3A after induction by St John's wort administration.
    Imai H; Kotegawa T; Tsutsumi K; Morimoto T; Eshima N; Nakano S; Ohashi K
    Br J Clin Pharmacol; 2008 May; 65(5):701-7. PubMed ID: 18294328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of St. John's wort supplementation on ibuprofen pharmacokinetics.
    Bell EC; Ravis WR; Lloyd KB; Stokes TJ
    Ann Pharmacother; 2007 Feb; 41(2):229-34. PubMed ID: 17284505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time-course effects of St John's wort on the pharmacokinetics of cyclosporine in dogs: interactions between herbal extracts and drugs.
    Fukunaga K; Orito K
    J Vet Pharmacol Ther; 2012 Oct; 35(5):446-51. PubMed ID: 22091645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John's Wort.
    Adiwidjaja J; Boddy AV; McLachlan AJ
    Clin Pharmacokinet; 2019 Jul; 58(7):911-926. PubMed ID: 30675694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No clinically relevant CYP3A induction after St. John's wort with low hyperforin content in healthy volunteers.
    Mueller SC; Majcher-Peszynska J; Mundkowski RG; Uehleke B; Klammt S; Sievers H; Lehnfeld R; Frank B; Thurow K; Kundt G; Drewelow B
    Eur J Clin Pharmacol; 2009 Jan; 65(1):81-7. PubMed ID: 18762932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.